FDA Report Supports Merck HIV Drug Approval
Posted on: Monday, 3 September 2007, 15:15 CDT
A document published by the FDA, ahead of a drug advisory committee meeting, has supported Merck & Co.'s HIV drug Isentress, which is currently under consideration for approval in the US.
The document, which reviews current data on Isentress (raltegravir), said that "the benefits of raltegravir in HIV-1 treatment-experienced subjects outweigh the currently identified risks." The drug is currently being evaluated in a Phase III study in treatment-naive patients.
Raltegravir is the first agent of the pharmacological class of antiretroviral agents known as integrase inhibitors to be submitted to FDA for review for marketing approval. The drug works by blocking one of the processes whereby HIV replicates itself.
The FDA analyses of the safety and efficacy data submitted in the NDA support Merck's findings, the document said. Phase II and III trial data provide evidence that the antiviral activity of raltegravir is superior to optimized background therapy in treatment-experienced patients with few or no remaining treatment options. The report concluded that raltegravir appeared to be well-tolerated in the Phase II and Phase III clinical studies with relatively few subjects discontinuing for adverse events.
The advisory committee will take the report into consideration when it meets to make its recommendations on approving the drug on September 5.
Source: Datamonitor
Related Articles
- New Report Contains In-Depth Analysis of Phase II and III Clinical Development Compounds for the Treatment of HIV
- Pfizer's Selzentry Treatment for HIV Approved By FDA
- Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved By FDA
- CORRECTING and REPLACING Columbia Laboratories Completes Treatment Phase of Phase III Study of PROCHIEVE 8% to Prevent Recurrent Preterm Birth
- Columbia Laboratories Completes Treatment Phase of Phase III Study of PROCHIEVE 8% to Prevent Recurrent Preterm Birth
- Recent Research on Leukemia Has Revealed 85 Drug Candidates in Phase II or III Stage of Development and More Than 50 Companies Are Involved In the Development of These Drugs
- New Data Confirm Durable Response of TNX-355 Regimens Through 48 Weeks in Treatment-Experienced HIV Patients
- Paying for HIV Drugs Endangers Treatment: MSF
- Cellegy Announces Update to Savvy Phase 3 HIV Prevention Trials
- Cellegy Announces 50% Enrollment in Phase 3 HIV Prevention Trial in Ghana
 |
 |
User Comments (0)
RSS Feeds